RemedyAtlas
Back

TUDCA

Supporting liver enzyme health and potentially reducing cellular stress in metabolic and neurodegenerative contexts.

supplement
Human trial evidenceTraditional useInteraction riskNeeds more research

TUDCA is a bioactive bile acid derivative currently under investigation for its role in mitigating liver stress and neuroinflammation. While traditionally linked to gallbladder health, recent trials are exploring its systemic safety.

Last reviewed June 13, 2026 · AI-assisted, human-reviewed
Tauroursodeoxycholic acid (TUDCA) is a water-soluble bile acid that is produced naturally in the body in small amounts. It is the taurine conjugate of ursodeoxycholic acid (UDCA), a compound with long-standing use in gastroenterology for gallbladder and liver health. Scientists have recently focused on TUDCA's potential as a cytoprotective agent, particularly in the context of endoplasmic reticulum (ER) stress. Ongoing research is exploring its efficacy in metabolic conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and neurodegenerative pathways. While UDCA is an FDA-approved treatment for certain cholestatic liver diseases, TUDCA is primarily investigated as a supplementary metabolite with potentially higher bioavailability in specific tissues.

Quick answer

What it is: Tauroursodeoxycholic acid (TUDCA) is a water-soluble bile acid that is produced naturally in the body in small amounts.

May support:Non-Alcoholic Fatty Liver Disease (NAFLD), Liver Disease

Evidence Summary

Research indicates that bile acid metabolism is often dysregulated in chronic conditions such as Multiple Sclerosis (MS) and liver disease. A 2025 RCT (n=47) focused on MS found that TUDCA supplementation was safe and that bile acid metabolites are predictive of disease progression, supporting the rationale for its use in stabilizing metabolic pathways.

Last reviewed · Jun 2026

Have you tried TUDCA?

Vote in 5 seconds. Add details if you want.

Your experience for Non-Alcoholic Fatty Liver Disease (NAFLD):

Commonly Combined With

Other remedies frequently used alongside this one — from curated relationships, community reports, and shared protocols.

Community signal breakdown

Where this remedy is being discussed across the web and community.

See Community Mentions

People Like Me insights

As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.

Community Discussions

What people say about TUDCA

Search on Reddit →

Latest News

Latest news on TUDCA

More on Google News →

Health Videos

Health videos on TUDCA

More on YouTube

Why It Works

TUDCA is thought to act as a chemical chaperone that reduces endoplasmic reticulum (ER) stress, prevents apoptosis, and stabilizes cell membranes through the modulation of bile acid signaling pathways.

How it works in more detail

At a cellular level, TUDCA helps regulate protein folding and prevents the accumulation of unfolded proteins, which is a hallmark of ER stress. By inhibiting the mitochondrial pathway of cell death (apoptosis), specifically by preventing the translocation of the pro-apoptotic protein Bax, TUDCA may protect hepatocytes and neurons. It also influences the TGR5 and FXR receptors, which play critical roles in bile acid metabolism and glucose homeostasis. In neurological models, TUDCA has been observed to penetrate the blood-brain barrier and potentially modulate neuroinflammatory responses.

How to use

Always consult a qualified clinician.

Editorial guidance

Suggested dosage
250–1000 mg/day
Research dosage range
Commonly studied in clinical settings at doses ranging from 500mg to 2,000mg per day, often divided into two doses.
Typical forms
capsule, powder
Quality markers
When purchasing TUDCA, look for products from reputable manufacturers that provide third-party testing for purity and potency. Ensure the product label clearly states "Tauroursodeoxycholic Acid" and lists the dosage per serving. Avoid products with excessive fillers or artificial ingredients.
Medication interactions
  • bile acid sequestrants
  • aluminum-based antacids
Avoid if
  • pregnancy
  • breastfeeding
  • bile duct obstruction

Community tips

No community tips yet — be the first to share what worked for you.

Suggested dosage

250–1000 mg/day

General guidance — discuss specifics with a clinician.

Active medicinal compounds

Tauroursodeoxycholic acid (TUDCA)

Traditional use

While UDCA (ursodeoxycholic acid) has a history of clinical use, TUDCA itself does not have a distinct traditional use in herbal medicine systems. Its application is primarily within modern biochemical and nutritional contexts.

Safety

Safety warnings

Generally reported as safe in recent clinical trials with few adverse effects. However, individuals with biliary obstruction or severe gallbladder issues should consult a physician, as bile acids can influence biliary flow.

Avoid if

  • pregnancy
  • breastfeeding
  • bile duct obstruction

Medication interactions

  • bile acid sequestrants
  • aluminum-based antacids

Reported side effects

  • diarrhea
  • nausea
  • abdominal discomfort

General guidance — discuss specifics with a clinician.

Evidence ecosystem

Scientific literature, clinical guidance, government sources, ongoing research, traditional use, and lived experience — grouped by source type and quality.

Overall grade

Research indicates that bile acid metabolism is often dysregulated in chronic conditions such as Multiple Sclerosis (MS) and liver disease. A 2025 RCT (n=47) focused on MS found that TUDCA supplementation was safe and that bile acid metabolites are predictive of disease progression, supporting the rationale for its use in stabilizing metabolic pathways.

Randomized Human Trials(1)

Controlled human studies with random assignment.

High Quality

  • Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.

    Ladakis DC, Harrison KL, Smith MD, Solem K, Gadani S, Jank L · Med (New York, N.Y.) · 2025 · n=47

    Bile acid metabolism is altered in multiple sclerosis (MS) and tauroursodeoxycholic acid (TUDCA) supplementation ameliorated disease in mouse models of MS. Global metabolomics was performed in an observational cohort of people with MS, followed by pathway analysis to examine relationships between baseline metabolite levels and subsequent brain and retinal atrophy. A double-blind, placebo-controlled trial was completed in people with progressive MS (PMS), randomized to receive either TUDCA (2 g/day) or placebo for 16 weeks. Participants were followed with serial clinical and laboratory assessments. Primary outcomes were safety and tolerability of TUDCA, and exploratory outcomes included changes in clinical, laboratory, and gut microbiome parameters. In the observational cohort, higher primary bile acid levels at baseline predicted slower whole-brain atrophy, brain substructure atrophy, and specific retinal layer atrophy. In the clinical trial, 47 participants were included in our

    Randomized TrialPubMedHigh Quality

Limitations: While safety data is emerging from RCTs, many therapeutic claims for TUDCA rely on animal models or small cohorts. Large-scale, long-term human trials are still required to confirm definitive efficacy for specific conditions like NAFLD or MS progression.

This page is educational. Statements use phrases like "may support" and "has been studied for"because no remedy here is approved to cure, treat, or reverse any condition. Discussion happens on the ailment pages — community statistics here are derived from those reports. Always consult a qualified clinician.

Tried TUDCA?

Help others see what actually works.